Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
- 30 April 2006
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 52 (1) , 67-74
- https://doi.org/10.1016/j.lungcan.2005.11.008
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality ProtocolJournal of Clinical Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized studyLung Cancer, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung CancerChest, 2000
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 TrialJNCI Journal of the National Cancer Institute, 1996
- Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.Journal of Clinical Oncology, 1995
- Current Treatment of Unresectable Lung CancerMayo Clinic Proceedings, 1993
- Controversies in the Nonsurgical Treatment of Stage III Non-small Cell Lung CancerAmerican Review of Respiratory Disease, 1992